Lyell Immunopharma (LYEL) Assets Average (2021 - 2026)

Lyell Immunopharma (LYEL) has 6 years of Assets Average data on file, last reported at $345.3 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 24.98% year-over-year to $345.3 million; the trailing twelve-month figure through Mar 2026 stood at $345.3 million (down 24.98% YoY), and the FY2025 full-year result was $415.5 million, down 33.04% from the prior year.
• Assets Average fell to $345.3 million in Q1 2026, from $374.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.1 billion in Q1 2022 to a low of $345.3 million in Q1 2026.
• A 5-year average of $707.7 million and a median of $722.1 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average fell 17.34% in 2023 and sank 39.54% in 2025, its largest moves.
• Tracing LYEL's Assets Average over 5 years: stood at $957.4 million in 2022, then fell by 19.31% to $772.5 million in 2023, then dropped by 28.15% to $555.0 million in 2024, then sank by 32.62% to $374.0 million in 2025, then fell by 7.67% to $345.3 million in 2026.
• Business Quant data shows LYEL's Assets Average at $345.3 million in Q1 2026, $374.0 million in Q4 2025, and $396.7 million in Q3 2025.